Recombinant human soluble thrombomodulin protects against brain injury in a CVST rat model, via downregulation of the HMGB1-RAGE axis

Molecular Medicine Reports

Volumn 14, Issue 6, 2016, Pages 5217-5222

  Gu, Jian Jun ^a   Chen, Jie Bin ^b   Zhang, Jian He ^a   Zhang, Hao ^a   Wang, Shou Sen ^a  

^a XIAMEN UNIVERSITY   (China)

^b NANTONG UNIVERSITY   (China)

Author keywords

Apoptosis; Cerebral venous sinus thrombosis; HMGB1 RAGE axis; Inflammation cytokines; Recombinant human soluble thrombomodulin

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; CASPASE 3; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; PROTEIN BAX; PROTEIN BCL 2; RECOMBINANT THROMBOMODULIN; TUMOR NECROSIS FACTOR; AUTACOID; BIOLOGICAL MARKER; CYTOKINE; RECOMBINANT PROTEIN; THROMBOMODULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INFARCTION; BRAIN INFARCTION SIZE; BRAIN TISSUE; BRAIN WATER; CEREBRAL SINUS THROMBOSIS; CONTROLLED STUDY; DOWN REGULATION; MALE; NEUROPROTECTION; NONHUMAN; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANIMAL; APOPTOSIS; BRAIN INJURIES; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION; GENETICS; HUMAN; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; ANIMALS; APOPTOSIS; BIOMARKERS; BRAIN INJURIES; CYTOKINES; DISEASE MODELS, ANIMAL; GENE EXPRESSION; HMGB1 PROTEIN; HUMANS; INFLAMMATION MEDIATORS; MALE; RATS; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; SINUS THROMBOSIS, INTRACRANIAL; THROMBOMODULIN;

EID: 84999233040     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2016.5891     Document Type: Article

References (26)

1. Bousser MG and Ferro JM: Cerebral venous thrombosis: An update. Lancet Neurol 6: 162-170, 2007.
2. Ruiz-Sandoval JL, Chiquete E, Bañuelos-Becerra LJ, Torres-Anguiano C, González-Padilla C, Arauz A, León-Jiménez C, Murillo-Bonilla LM, Villarreal-Careaga J, Barinagarrementería F, et al: Cerebral venous thrombosis in a Mexican multicenter registry of acute cerebrovascular disease: The RENAMEVASC study. J Stroke Cerebrovasc Dis 21: 395-400, 2012.
3. Schaller B and Graf R: Cerebral venous infarction: The pathophysiological concept. Cerebrovasc Dis 18: 179-188, 2004.
4. Guenther G and Arauz A; Cerebral venous thrombosis: A diagnostic and treatment update. Neurologia 26: 488-498, 2011.
5. Camerlingo M, Salvi P, Belloni G, Gamba T, Cesana BM and Mamoli A: Intravenous heparin started within the first 3 hours after onset of symptoms as a treatment for acute nonlacunar hemispheric cerebral infarctions. Stroke 36: 2415-2420, 2005.
6. Esmon CT and Owen WG: Identifi cation of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. Proc Natl Acad Sci USA 78: 2249-2252, 1981.
7. Lane DA, Philippou H and Huntington JA: Directing thrombin. Blood 106: 2605-2612, 2005.
8. Conway EM, Van de Wouwer M, Pollefeyt S, Jurk K, Van Aken H, De Vriese A, Weitz JI, Weiler H, Hellings PW, Schaeffer P, et al: The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor kappaB and mitogen-activated protein kinase pathways. J Exp Med 196: 565-577, 2002.
9. Su EJ, Geyer M, Wahl M, Mann K, Ginsburg D, Brohmann H, Petersen KU and Lawrence DA: The thrombomodulin analog Solulin promotes reperfusion and reduces infarct volume in a thrombotic stroke model. J Thromb Haemost 9: 1174-1182, 2011.
10. Ryang YM, Dang J, Kipp M, Petersen KU, Fahlenkamp AV, Gempt J, Wesp D, Rossaint R, Beyer C and Coburn M: Solulin reduces infarct volume and regulates gene-expression in transient middle cerebral artery occlusion in rats. BMC Neurosci 12: 113, 2011.
11. Huang Z, Huang PL, Panahian N, Dalkara T, Fishman MC and Moskowitz MA: Effect of cerebral ischemia in mice defi cient in neuronal nitric oxide synthase. Science 265: 1883-1885, 1994.
12. Weimar C: Diagnosis and treatment of cerebral venous and sinus thrombosis. Curr Neurol Neurosci Rep 14: 417, 2014.
13. Esmon CT: The protein C pathway. Chest 124 (Suppl 3): 26S-32S, 2003.
14. Wenzel J, Assmann JC and Schwaninger M: Thrombomodulin-a new target for treating stroke at the crossroad of coagulation and inflammation. Curr Med Chem 21: 2025-2034, 2014.
15. Van de Wouwer M, Plaisance S, De Vriese A, Waelkens E, Collen D, Persson J, Daha MR and Conway EM: The lectin-like domain of thrombomodulin interferes with complement activation and protects against arthritis. J Thromb Haemost 4: 1813-1824, 2006.
16. Ito T and Maruyama I: Thrombomodulin: Protectorate God of the vasculature in thrombosis and infiammation. J Thromb Haemost 9 (Suppl 1): S168-S173, 2011.
17. Lai CH, Shi GY, Lee FT, Kuo CH, Cheng TL, Chang BI, Ma CY, Hsu FC, Yang YJ and Wu HL: Recombinant hman thrombomodulin suppresses experimental abdominal aortic aneurysms induced by calcium chloride in mice. Ann Surg 258: 1103-1110, 2013.
18. Javanmard SH, Shahsavarzadeh T and Saadatnia M: Soluble thrombomodulin and endothelial cell protein C receptor levels in patients with cerebral venous and sinus thrombosis. Eur Neurol 70: 156-158, 2013.
19. Scaffidi P, Misteli T and Bianchi ME: Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418: 191-195, 2002.
20. Andrassy M, Volz HC, Igwe JC, Funke B, Eichberger SN, Kaya Z, Buss S, Autschbach F, Pleger ST, Lukic IK, et al: High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation 117: 3216-3226, 2008.
21. Abeyama K, Stern DM, Ito Y, Kawahara K, Yoshimoto Y, Tanaka M, Uchimura T, Ida N, Yamazaki Y, Yamada S, et al: The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J Clin Invest 115: 1267-1274, 2005.
22. Tsung A, Klune JR, Zhang X, Jeyabalan G, Cao Z, Peng X, Stolz DB, Geller DA, Rosengart MR and Billiar TR: HMGB1 release induced by liver ischemia involves Toll-like receptor 4 dependent reactive oxygen species production and calcium-mediated signaling. J Exp Med 204: 2913-2923, 2007.
23. Rauvala H and Rouhiainen A: Physiological and pathophysiological outcomes of the interactions of HMGB1 with cell surface receptors. Biochim Biophys Acta 1799: 164-170, 2010.
24. Schmidt AM, Yan SD, Yan SF and Stern DM: The multiligand receptor RAGE as a progression factor amplifying immune and infl ammatory responses. J Clin Invest 108: 949-955, 2001.
25. Ito T, Kawahara K, Okamoto K, Yamada S, Yasuda M, Imaizumi H, Nawa Y, Meng X, Shrestha B, Hashiguchi T and Maruyama I: Proteolytic cleavage of high mobility group box 1 protein by thrombin-thrombomodulin complexes. Arterioscler Thromb Vasc Biol 28: 1825-1830, 2008.
26. Yang H, Meng Z, Zhang C, Zhang P and Wang Q: Establishing a new rat model of central venous sinus thrombosis and analyzing its pathophysiological and apoptotic changes. J Neurosci Methods 203: 130-135, 2012.